Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Critical Care ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mechanisms of thrombus formation.N Engl J Med. 2008; 359: 938-949
- Platelet adhesion receptors and (patho)physiological thrombus formation.Histol Histopathol. 2001; 16: 969-980
- Function of von Willebrand factor in haemostasis and thrombosis.Haemophilia. 2008; 14: 11-26
- Cell adhesion mechanisms in platelets.Arterioscler Thromb Vasc Biol. 2008; 28: 403-412
- Mechanisms initiating platelet thrombus formation.Thromb Haemost. 1997; 78: 611-616
- The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis.Curr Pharm Des. 2004; 10: 1567-1576
- Inflammation and the activated protein C anticoagulant pathway.Semin Thromb Hemost. 2006; 32: 49-60
- Vascular-bed-specific hemostasis and hypercoagulable states.N Engl J Med. 1999; 340: 1555-1564
- Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes.J Biol Chem. 1991; 266: 14580-14584
- The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis.Hematol Oncol Clin North Am. 2000; 14 (vii): 325-338
- The plasminogen activator system and cancer.Pathophysiol Haemost Thromb. 2008; 36: 184-194
- De l-Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general.Arch Gen Med. 1823; 1 ([in French]): 188-204
- Phlegmasia alba dolens.in: Trousseau A. Clinique medicinale de l'Hotel-Dieu de Paris. 2nd edition. Bailliere J.-B. et fils, Paris (France)1865: 645-712
- Cancer and thrombosis: from molecular mechanisms to clinical presentations.J Thromb Haemost. 2007; 5: 246-254
- Lectures on surgical pathology and therapeutics: a handbook for students and practitioners.in: Hackley C.E. D. Appelton and Company, New York (NY)1877
- Disseminated intravascular coagulation (DIC) in cancer.Cancer Treat Res. 2009; 148: 137-156
- Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues.Blood Coagul Fibrinolysis. 2009; 20: 315-320
- Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.Thromb Res. 2009; 124: 364-367
- Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture.Blood. 1989; 73: 159-165
- Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.J Exp Med. 1986; 163: 1595-1600
- Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.Arch Intern Med. 2000; 160: 761-768
- Malignancies, prothrombotic mutations, and the risk of venous thrombosis.JAMA. 2005; 293: 715-722
- Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?.South Med J. 1980; 73: 841-843
- JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.Blood. 2009; 113: 5617-5623
- Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?.Ann Intern Med. 2008; 149: 323-333
- Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study.Lancet Oncol. 2007; 8: 395-402
- The effect of anticoagulants on cancer risk and survival: systematic review.Cancer Treat Rev. 2007; 33: 358-368
- Coagulopathic complications of cancer patients.in: Kufe D.W. Cancer medicine. 7th edition. BC Decker, Hamilton (ON) Canada2006
- Bleeding, clotting and cancer.Clin Oncol (R Coll Radiol). 1997; 9: 294-301
- Coagulation disorders in the ICU.Clin Chest Med. 2009; 30 (ix): 123-129
- Bleeding and thrombotic complications in critically ill patients with cancer.Crit Care Clin. 2001; 17: 599-622
- Niche-to-niche migration of bone-marrow-derived cells.Trends Mol Med. 2007; 13: 72-81
- The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production.Oncogene. 2002; 21: 3359-3367
- Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.Nat Med. 2004; 10: 64-71
- Evidence-based platelet transfusion guidelines.Hematology Am Soc Hematol Educ Program. 2007; : 172-178
- Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol. 2001; 19: 1519-1538
- Management of bleeding complications of hematologic malignancies.Semin Thromb Hemost. 2007; 33: 427-434
- Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?.J Thromb Haemost. 2008; 6: 565-568
- Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.Semin Hematol. 2006; 43: S48-S58
- Therapeutic approaches to acquired von Willebrand syndrome.Expert Opin Investig Drugs. 2000; 9: 347-354
- Use of recombinant factor VIIa in inherited and acquired von Willebrand disease.Clin Appl Thromb Hemost. 2009; 15: 27-31
- Acquired hemophilia in a patient affected by acute myeloid leukemia.Am J Hematol. 2005; 79: 81-82
- Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland.Ann Hematol. 2009; 88: 365-370
- The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.Thromb Res. 2007; 119: 723-729
- Recombinant human erythropoietin treatment improves platelet function in uremic patients.Kidney Int. 1992; 42: 668-672
- Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients.Thromb Haemost. 1999; 82: 1312-1317
- Evidence-based treatment recommendations for uremic bleeding.Nat Clin Pract Nephrol. 2007; 3: 138-153
- Recombinant human erythropoietin to correct uremic bleeding.Am J Kidney Dis. 1991; 18: 44-49
- Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.Thromb Haemost. 1991; 66: 638-647
- Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression.Blood. 1994; 83: 161-166
- Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function.Am J Hematol. 1998; 59: 105-109
- Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.Semin Thromb Hemost. 2007; 33: 313-320
- Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.Am J Hematol. 2009; 84: 102-108
- Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Leukemia. 2008; 22: 1494-1502
- Annexin II and bleeding in acute promyelocytic leukemia.N Engl J Med. 1999; 340: 994-1004
- Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.Leuk Res. 2005; 29: 347-351
- Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008; 133: 160S-198S
- Critical care clotting catastrophies.Crit Care Clin. 2005; 21: 531-562
- Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD.Pathophysiol Haemost Thromb. 2003; 33: 50-53
- Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.JAMA. 2006; 295: 293-298
- Recombinant activated factor VII for acute intracerebral hemorrhage.N Engl J Med. 2005; 352: 777-785
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.J Thromb Haemost. 2004; 2: 1700-1708
- Thrombosis and recombinant factor VIIa.J Thromb Haemost. 2004; 2: 1698-1699
- Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells.J Urol. 2003; 169: 1157-1161
- Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies.Am J Clin Pathol. 1979; 71: 10-16
- Hemostasis and malignancy.Semin Thromb Hemost. 1998; 24: 93-109
- Venous thromboembolism and cancer.Blood Coagul Fibrinolysis. 1992; 3: 451-460
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.Blood. 2002; 100: 3484-3488
- Cancer and clots: all cases of venous thromboembolism are not treated the same.Cleve Clin J Med. 2009; 76: 129-135
- Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.N Engl J Med. 2003; 349: 146-153
- Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.J Clin Oncol. 2005; 23: 2123-2129
- Risk of venous thromboembolism with bevacizumab in cancer patients.JAMA. 2009; 301 ([author reply: 1435–6]): 1434-1435
- Thalidomide and thrombosis. A meta-analysis.Thromb Haemost. 2007; 97: 1031-1036
- Thrombosis in multiple myeloma.Expert Rev Anticancer Ther. 2007; 7: 307-315
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.Eur J Cancer. 2007; 43: 258-270
- Accuracy of clinical assessment of deep-vein thrombosis.Lancet. 1995; 345: 1326-1330
- Value of assessment of pretest probability of deep-vein thrombosis in clinical management.Lancet. 1997; 350: 1795-1798
- D-dimer assay to exclude pulmonary embolism in high-risk oncologic population: correlation with CT pulmonary angiography in an urgent care setting.Radiology. 2008; 247: 854-861
- The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism.Ann Intern Med. 1998; 129: 1044-1049
- Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition.Chest. 2008; 133: 454S-545S
- Management of venous thromboembolism in the intensive care unit.J Crit Care. 2009; 24: 185-191
- Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor.J Intensive Care Med. 2006; 21: 240-245
- Postthrombotic syndrome in relation to vena cava filter placement: a systematic review.J Vasc Interv Radiol. 2008; 19: 981-985
- Use of inferior vena caval filters and survival in patients with malignancy.Cancer. 2004; 101: 1902-1907
- Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008; 133: 381S-453S
- Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.Br J Surg. 2005; 92: 1212-1220
- Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.N Engl J Med. 2002; 346: 975-980
- Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis.Cancer Treat Rev. 2002; 28: 141-144
- Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.Ann Intern Med. 1990; 112: 423-428
- Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin).Thromb Haemost. 1996; 75: 251-253
- Complication rates among cancer patients with peripherally inserted central catheters.J Clin Oncol. 2002; 20: 3276-3281
- Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.J Vasc Interv Radiol. 2001; 12: 951-955
- Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer.Oncologist. 2003; 8: 375-380
- Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.N Engl J Med. 1998; 339: 1585-1594
- Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.J Thromb Haemost. 2004; 2: 1601-1609
- Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.Br J Haematol. 2006; 134: 187-195
- Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.Cancer Res. 1999; 59: 2244-2250
- Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).Haematologica. 2003; 88: 454-458
- Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.Thromb Res. 2002; 106: 127-130
- Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura.Ann Hematol. 2005; 84: 232-235
- Thrombotic thrombocytopenic purpura: 2008 update.Cleve Clin J Med. 2008; 75: 369-375
- Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura.Transfusion. 2009; 49: 873-887
- Cancer and DIC.Haemostasis. 2001; 31: 47-48
- Molecular basis for the relationship between thrombosis and cancer.Thromb Res. 2001; 102: V215-V224
- Guidelines for the diagnosis and management of disseminated intravascular coagulation.Br J Haematol. 2009; 145: 24-33
- The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.J Thromb Haemost. 2007; 5: 604-606
- Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation.Crit Care Med. 2004; 32: 2416-2421
- Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.Best Pract Res Clin Haematol. 2003; 16: 463-482
- Prevention and treatment of major blood loss.N Engl J Med. 2007; 356: 2301-2311
- Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition.Chest. 2008; 133: 340S-380S
- An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.Arch Intern Med. 2003; 163: 2518-2524
- Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis.N Engl J Med. 2007; 356: 891-893
- Heparin-induced thrombocytopenia.Hematol Oncol Clin North Am. 2007; 21 (v): 589-607
- Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia.Blood. 2006; 108: 2937-2941
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.J Thromb Haemost. 2006; 4: 759-765
- Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.Cancer. 2003; 97: 3099-3106
- The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.Curr Opin Oncol. 2008; 20: 690-696
- Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development.Clin Pharmacokinet. 2009; 48: 1-22
- Dabigatran etexilate.Drugs. 2008; 68: 1699-1709
- Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.Expert Opin Investig Drugs. 2008; 17: 773-777
Article info
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
